Analysis of the clinical application effect of Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction
Ma Chao
Zhang Qinglin
Xu Xiaodong
Fang Zhong
Jiang Xuehong
Abstract：Objective To evaluate the clinical efficacy of dapagliflozin in patients with heart failure characterized by mid-range or preserved ejection fraction.Methods 112 patients with mildly reduced or reserved ejection fraction who were hospitalized in the Department of Cardiology of our hospital from January 2022 to April 2023 were selected as the research objects,and were randomly divided into Dapagliflozin group(n=54)and control group(n=58).Both groups were given routine basic treatment,and Dapagliflozin group was given Dapagliflozin 10 mg daily.Six months after discharge,the changes of left ventricular end diastolic diameter(LVEDD),left ventricular ejection fraction(LVEF)and B-type brain natriuretic peptide(BNP)before and after treatment were compared between the two groups.The changes of LVEDD,LVEF and lgBNP in Dapagliflozin group and control group after 6 months of treatment were compared respectively.Finally,the occurrence of(major adverse cardiovascular events)MACE in two groups was analyzed after 6 months of discharge.Results After treatment,the LVEDD and lgBNP levels in the Dapagliflozin group were lower than those in the control group,the LVEF level was higher than that in the control group,with statistical differences(t=-2.033,2.020,-2.253,P<0.05).The incidence of MACE in the Dapagliflozin group was 11.11%lower than that in the control group(27.59%)at 6 months after discharge(χ2=5.657,P=0.017).Conclusion Dapagliflozin can improve the clinical therapeutic effect of patients with intermediate ejection fraction or reserved heart failure,and reduce the occurrence of MACE.
Keywords：DapagliflozinMildly reduced ejection fractionPreserved ejection fractionHeart failure
Publication Date：2025-02-27
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 58-61 )